Von Hippel-Lindau disease: Recent advances in genetics and clinical management;Maladie de Von Hippel-lindau: Progrès génétiques et cliniques récents

Journal of Neuroradiology

Volumn 32, Issue 3, 2005, Pages 157-167

  Richard, S ^a,b,c   Parker, F ^c   Aghakhani, N ^c   Allegre, G ^a,b   Portier, F ^c   David, P ^c   Marsot Dupuch, K ^c  

^a PSL RESEARCH UNIVERSITY   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c BICÊTRE HOSPITAL   (France)

Author keywords

Hemangioblastoma; Hypoxia inducible factor; PTK inhibitors; Renal cell carcinoma; Von Hippel Lindau

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; PROTEASOME; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; CANCER SUSCEPTIBILITY; CENTRAL NERVOUS SYSTEM TUMOR; CLEAR CELL CARCINOMA; DIAGNOSTIC IMAGING; ENDOLYMPHATIC SAC; FAMILIAL CANCER; GENE CONTROL; GENE INACTIVATION; GENE MUTATION; HEMANGIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; NEUROENDOCRINE TUMOR; OXYGEN SENSING; PATHOPHYSIOLOGY; PHEOCHROMOCYTOMA; PROTEIN DEGRADATION; REVIEW; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; VON HIPPEL LINDAU DISEASE;

EID: 20844442616     PISSN: 01509861     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0150-9861(05)83133-5     Document Type: Review

References (34)

1. AIELLO LP, GEORGE DJ, CAHILL MT et al. Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor SU5416. Ophthalmology 2002; 109: 1745-1751,
2. ANG SO, CHEN H, HIROTA K et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002; 32: 614-621.
3. BENDER BU, ENG C, OLSCHEWSKI M et al. VHL c.505 T>C mutation confers a high age related penetrance but no increased overall mortality. J Med Genet 2001; 38: 508-514.
4. CHANG SD, MEISEL JA, HANCOCK SL, MARTIN DP, MCMANUS M, ADLER JR Jr. Treatment of hemangioblastomas in von Hippel-Lindau disease with linear accelerator-based radiosurgery. Neurosurgery 1998; 43: 28-35.
5. CHAUVEAU D, DUVIC C, CHRÉTIEN Y et al. Renal involvement in von Hippel-Lindau disease. Kidney Int 1996; 50: 944-951.
6. DATTA K, SUNDBERG, KARUMANCHI SA, MUKHOPADHYAY D. The 104-123 amino acid sequence of the β-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res 2001; 61: 1768-1775.
7. DOLLFUS H, MASSIN P, TAUPIN P et al. Ocular manifestations in von Hippel-Lindau disease: a clinical and molecular study. Invest Ophthalmol Vis Sci 2002; 43: 3067-3074.
8. FABBRO D, PARKINSON D, MATTER A. Protein tyrosine kinase inhibitors: new treatment modalities? Curr Opin Pharmacol 2002; 2: 374-381.
9. GIRAUD S, PLAUCHU H, DOLLFUS H, RICHARD S. La maladie de von Hippel-Lindau. Fiche de recommendations de la Société Française de Génétique Humaine. Les Cahiers du diagnostic génétique, INSERM, 2001.
10. GIRMENS JF, ERGINAY A, MASSIN P, SCIGALLA P, GAUDRIC A, RICHARD S. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Am J Ophthalmol 2003; 136: 194-196.
11. HAASE VH, GLICKMAN JN, SOCOLOVSKY M, JAENISH R. Vascular tumors in liver with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci 2001; 98: 1583-1588.
12. HAMMEL P, VILGRAIN V, TERRIS B et al. Pancreatic involvement in von Hippel-Lindau's disease: prevalence, course and impact in the management of patients. Gastroenterology 2000; 119: 1087-1095.
13. HERRING JC, ENQUIST EG, CHERNOFF A, LINEHAN WM, CHOYKE P, WALTHER McM. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol 2001; 165: 777-781.
14. HES FJ, HOPPENER JW, LIPS CJ. Clinical review 155: Pheochromocytoma in von Hippel-Lindau disease. J Clin Endocrinol Metab 2003; 88: 969-974.
15. HOFFMAN MA, OHH M, YANG H, KLCO JM, IVAN M, KAELIN Jr WG Jr. Von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet 2001; 10: 1019-1027.
16. KAELIN WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2: 673-682.
17. LONSER RR, GLENN G, WALTHER McC, CHEW EY, LIBUTTI SK, LINEHAN WM, OLDFIELD EH. Von-Hippel-Lindau disease. Lancet 2003; 361: 2059-2067.
18. MANSKI TJ, HEFFNER DK, GLENN GM et al. Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. MMA 1997; 277: 1461-1466.
19. MAXWELL PH, WIESENER MS, CHANG GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275.
20. NEUMANN HPH, BENDER BU, BERGER DP et al. Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. J Urol 1998; 160: 1248-1254.
21. NEUMANN HPH, BAUSH B, MCWHINNEY SR et al. Germline mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346: 1459-1466.
22. NIEMELÄ M, LIM YJ, SÖDERMAN M, JÄÄSKELAINÄINEN J, LINDQUIST C. Gamma knife radiosurgery in 11 hemangioblastomas. J Neurosurg 1996; 85: 591-596.
23. NIEMELÄ M, MÄENPÄÄ H, SALVEN P et al. Interferon-2α therapy in 18 hemangioblastomas. Clin Cancer Res 2001; 7: 510-516.
24. OLSCHWANG S, RICHARD S, BOISSON C et al. Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma. Hum Mutat 1998; 12: 424-430.
25. PASTORE YD, JELINEK J, ANG S et al. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 2003; 101: 1591-1595.
26. PAVLOVICH CP, WALTHER McCM, CHOYKE PL et al. Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol 2002; 167: 10-15.
27. RICHARD S, DAVID Ph, MARSOT-DUPUCH K et al. Central nervous system hemangioblastomas, endolymphatic sac tumors and von Hippel-Lindau disease. Neurosurg Rev 2000; 23: 1-22.
28. RICHARD S. Von Hippel-Lindau disease: recent advances and therapeutic perspectives. Exp Rev Anticancer Therapy 2003; 3: 215-233.
29. RICHARD S, GRAFF J, LINDAU J, RESCHE F. Von Hippel-Lindau disease. Lancet 2004; 363: 1231-1234.
30. SEMENZA GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002; 8: S27-S31.
31. VORTMEYER AO, FRANK S, JEONG S et al. Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Res 2003; 63: 7051-7055.
32. WANEBO JE, LONSER RR, GLENN GM, OLDFIELD EH. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg 2003; 98: 82-94.
33. WEBSTER AR, RICHARDS FM, MACRONALD FE, MOORE AT, MAHER ER. An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease : evidence for modifier effects. Am J Hum Genet 1998; 63: 1025-1035.
34. ZBAR B, KISHIDA T, CHEN F et al. Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996; 8: 348-357.